CRISPR Therapeutics AG Ratios

Ratios Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -10,453.85%-439.93%-162.47%-5,263.38%23.24%-49,469.54%41.48%-54,409.10%-48.78%-1,082.43%
EBIT Margin -10,416.60%-1,319.33%-157.69%-5,087.80%16.14%-49,295.55%40.82%-56,190.40%-59.95%-1,250.38%
EBITDA Margin -10,459.11%-449.65%-166.64%-5,281.79%23.09%-48,533.38%40.73%-55,154.84%-36.65%-981.74%
Operating Margin -10,416.60%-1,319.33%-157.69%-5,087.80%16.14%-49,295.55%40.82%-56,190.40%-59.95%-1,250.38%
Net Margin -10,478.54%-451.96%-166.74%-5,281.08%23.09%-49,582.06%41.28%-54,466.28%-49.67%-1,093.34%
FCF Margin 23,592.71%-1,159.45%-190.03%-3,169.40%17.26%-35,705.70%49.98%-44,484.89%-72.69%-387.72%
Efficiency
Assets Average 0.25B0.31B0.38B0.78B1.45B2.29B2.50B2.24B2.24B
Equity Average 0.10B0.21B0.29B0.67B1.30B2.03B2.14B1.88B1.91B
Invested Capital -0.03B0.23B0.19B0.39B0.94B1.66B2.40B1.88B1.88B1.93B
Asset Utilization Ratio 0.020.130.010.370.000.400.000.170.02
Leverage & Solvency
Equity Ratio -0.180.670.690.800.880.910.870.840.840.86
Valuation
Enterprise Value -0.16B0.52B0.72B1.62B2.57B9.13B3.42B1.37B3.28B1.46B
Market Capitalization 0.84B0.96B2.07B3.51B10.82B5.80B3.18B4.97B3.36B
Return Ratios
Return on Sales -104.79%-4.52%-1.67%-52.81%0.23%-495.82%0.41%-544.66%-0.50%-10.93%
Return on Capital Employed -0.30%-0.22%-0.45%0.06%-0.26%0.17%-0.28%-0.10%-0.22%
Return on Invested Capital 0.07%0.18%
Return on Assets -0.09%-0.22%-0.43%0.09%-0.25%0.16%-0.26%-0.08%-0.18%
Return on Equity -0.23%-0.32%-0.57%0.10%-0.27%0.19%-0.31%-0.10%-0.21%